2. Signaling Pathways
  3. Membrane Transporter/Ion Channel
  4. ATP Synthase

ATP Synthase

ATP Synthase

Related Products

PDF 0.2 MB

ATPases are a class of enzymes that catalyze the decompositionof ATP into ADP and a free phosphate ion. This dephosphorylation reaction releases energy, which the enzyme (in most cases) harnesses to drive other chemical reactions that would not otherwise occur. Some such enzymes are integral membrane proteins and move solutes across the membrane, typically against their concentration gradient. These are called transmembrane ATPases. Transmembrane ATPases import many of the metabolites necessary for cell metabolism and export toxins, wastes, and solutes that can hinder cellular processes. Such as the sodium-potassium exchanger (or Na+/K+ ATPase) and the hydrogen potassium ATPase (H+/K+ ATPase or gastric proton pump) that acidifies the contents of the stomach.

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-158415
    ATPase-IN-4
    		Inhibitor ≥98.0%
    ATPase-IN-4 (Compound MS1) inhibits the ATPase activity of EHD4 (IC50: 0.92 μM). ATPase-IN-4 also inhibits EHD2 enzymatic activity
    ATPase-IN-4
  • HY-150983
    ATP synthase inhibitor 2
    		Inhibitor 99.93%
    ATP synthase inhibitor 2 is a Pseudomonas aeruginosa (PA) ATP synthase inhibitor (IC50=10 μg/mL). ATP synthase inhibitor 2 can inhibit Pseudomonas aeruginosa (PA) ATP synthesis activity completely at 128 μg/mL.
    ATP synthase inhibitor 2
  • HY-148973
    ZW290
    		Inhibitor 99.60%
    ZW290 is a compound to activate brown adipose tissue (BAT) thermogenic function. ZW290 increases the expression of uncoupling Protein 1 (UCP1) protein and inhibits ATP synthesis in BAT.
    ZW290
  • HY-146388
    Mtb ATP synthase-IN-1
    		Inhibitor 98.55%
    Mtb ATP synthase-IN-1 (compound 6ab) is a potent Mycobacterium tuberculosis (Mtb) ATP synthase inhibitor, with MIC of 0.452-0.499 μg/mL against Mtb. Mtb ATP synthase-IN-1 has good metabolic stability, low cytotoxicity (Vero IC50 > 64 μg/mL), and acceptable oral bioavailability. Mtb ATP synthase-IN-1 can be used for researching anti-mycobacterium.
    Mtb ATP synthase-IN-1
  • HY-131800
    3'-NH2-ATP
    3'-NH2-ATP, an ATP analogue, is a potent and competitive inhibitor of ATP, with a Ki of 2.3 μM. 3'-NH2-ATP can be used to synthesis of 3′-Amino-3′-deoxy transfer RNA by incorporation into the 3' terminus of tRNA-C-C.
    3'-NH2-ATP
  • HY-10250S1
    Triciribine phosphate-d3
    		Inhibitor
    Triciribine phosphate-d3 (TCN-P-d3) is a deuterated compound of Triciribine phosphate (TCN-P). TCN-P inhibits adenosine monophosphate (AMP)-activated protein kinase through an allosteric mechanism, affecting the first key step in de novo purine biosynthesis. Triciribine phosphate also inhibits inosine monophosphate dehydrogenase, which is the first key step in guanosine nucleotide synthesis. Triciribine phosphate does not affect ligase activity .
    Triciribine phosphate-d<sub>3</sub>
  • HY-113126A
    3-Hydroxyisobutyric acid sodium
    		Inhibitor
    3-Hydroxyisobutyric acid sodium is an intermediate in the metabolic pathways of L-valine and thymine, and can be found in urine. 3-Hydroxyisobutyric acid sodium is a secreted mediator of endothelial cell fatty acid transport and insulin resistance. 3-Hydroxyisobutyric acid sodium can also inhibit key enzymes of energy metabolism in the cerebral cortex of young rats. The levels of 3-Hydroxyisobutyric acid sodium are closely related to various diseases such as 3-hydroxyisobutyric aciduria, diabetes, and ketoacidosis.
    3-Hydroxyisobutyric acid sodium
  • HY-121908
    FCPT
    		Inhibitor
    FCPT, an ATP competitive inhibitor, induces a tight-binding of kinesin-5 onto microtubules and induced loss of microtubules selectively at the poles of Xenopus extract spindles without altering microtubule dynamics.
    FCPT
  • HY-P11005
    P259
    P259 is a Drp1-Mff inhibitor. P259 distinguishes physiological from pathological fission by specifically inhibiting Drp1-Mff interaction. P259 elongates cell mitochondria and disrupts mitochondrial function and motility. P259 reduces ATP levels and alters mitochondrial structure in the brain, resulting in behavioral deficits in wild-type mice and a short lifespan in Huntington's disease (HD) mice model.
    P259
  • HY-W017540S
    Cyclocreatine-13C3
    Cyclocreatine-13C3 is the 13C-labeled Cyclocreatine (HY-W017540). Cyclocreatine, a creatine analogue, acts as a brain-penetrant and potent bioenergetic protective agent by providing high levels of ATP. Cyclocreatine can be phosphorylated and dephosphorylated by creatine kinases. Cyclocreatine suppresses creatine metabolism ameliorating the cognitive, autistic and epileptic phenotype in a mouse model of creatine transporter defciency. Cyclocreatine protects against ischemic injury and enhances cardiac recovery during early reperfusion in dogs and rats. Cyclocreatine decreases plaque-adjacent neuronal dystrophy in TREM2-deficient mice with amyloid-β pathology. Cyclocreatine is proming for research of ischemic heart disease, cardiovascular diseases, Alzheimer’s disease and other neurodegenerative diseases associated with microglial dysfunction, prostate cancer.
    Cyclocreatine-<sup>13</sup>C<sub>3</sub>
  • HY-168006
    NSC819701
    		Inhibitor
    NSC819701 is a triazole inhibitor of the p97 ATPase. NSC819701 inhibits the activity of p97 ATPase by binding to a specific site of p97.
    NSC819701
  • HY-162804
    ATP synthase inhibitor 3
    		Inhibitor
    ATP synthase inhibitor 3 (compound PT6) is an orally active inhibitor of mycobacterial F-ATP synthase (IC50=0.788 μM). ATP synthase inhibitor 3 inhibits the growth of Mycobacterium tuberculosis H37Rv strain (ATCC-27294) in vitro and depletes intracellular ATP levels at an IC50 value of 30μM.
    ATP synthase inhibitor 3
  • HY-125637
    Venturicidin B
    		Inhibitor
    Venturicidin B (Aabomycin A2) is a macrolide antibiotic isolated from Streptomyces sp., used as an antifungal agent, a potent inhibitor of the mitochondrial F0-ATP synthase complex.
    Venturicidin B
  • HY-149736
    ATP Synthesis-IN-3
    		Activator
    ATP Synthesis-IN-3 (compound 31) is an ATP hydrolysis inhibitor with protective effects during myocardial ischemia. ATP Synthesis-IN-3 can increase the ATP content of ischemic cardiomyocytes, increase the phosphorylation of PKA and phospholamban, and inhibit ischemia-induced apoptosis.
    ATP Synthesis-IN-3
  • HY-118960A
    BMS-199264
    		Modulator
    BMS-199264 is an inhibitor of F1F0 ATP hydrolase (IC50=0.5 μM) without inhibitory effect on F1F0 ATP synthase. BMS-199264 selectively inhibits ATP decline during ischemia to reduces cardiac necrosis. BMS-199264 also enhances the recovery of contractile function following reperfusion.
    BMS-199264
  • HY-141505
    Ovothiol A disulfide
    		Inhibitor
    Ovothiol A disulfide is an inhibitor of light-triggered CF1 ATPase activity.
    Ovothiol A disulfide
  • HY-168005
    NSC799462
    		Inhibitor
    NSC799462 is a triazole inhibitor of p97 ATPase. NSC799462 inhibits p97 ATPase activity (IC50 = 15 nM) by binding to a specific site on p97 and causing local changes in the p97 structure.
    NSC799462
  • HY-150983A
    ATP synthase inhibitor 2 TFA
    		Inhibitor 99.97%
    ATP synthase inhibitor 2 (Compound 22) TFA is a Pseudomonas aeruginosa (PA) ATP synthase inhibitor (IC50=10 μg/mL). ATP synthase inhibitor 2 TFA can inhibit Pseudomonas aeruginosa (PA) ATP synthesis activity completely at 128 μg/mL.
    ATP synthase inhibitor 2 TFA
  • HY-174981
    LC-MF-4
    		Inhibitor
    LC-MF-4 is a selective FGFR3 PROTAC degrader with a DC50 of 30.89 nM in KMS-11 cells. LC-MF-4 inhibits the metabolic function of FGFR3-TACC3 fusion positive cancers with reduction of ATP synthesis and inhibition of mitochondrial biogenesis genes. LC-MF-4 has potent antitumor activity in the Ba/F3-FGFR3-TACC3 xenograft mice model. LC-MF-4 can be used for FGFR3-altered cancers like bladder cancer and urothelial carcinoma (UC) research. Pink: FGFR3 ligand (HY-175414); Blue: VHL ligase ligand (HY-125905); Black: linker (HY-Y1224)
    LC-MF-4
  • HY-175238
    KI-DX-014
    		Modulator
    KI-DX-014 is a DDX21 inhibitor with an IC50 of 3.31  μM. KI-DX-014 significantly inhibits the DDX21-RNA interaction and modulates ATPase activity and biomolecular condensate formation. KI-DX-014 reduces the DDX21-dependent release of P-TEFb from the 7SK snRNP complex, inhibits P-TEFb-dependent phosphorylation of the RNA polymerase II CTD, and induces developmental defects in zebrafish embryos. KI-DX-014 can be used for cancers and neurodegenerative disorders research.
    KI-DX-014
Cat. No. Product Name / Synonyms Application Reactivity